Evogene (EVGN) Current Deferred Revenue (2016 - 2018)

Evogene (EVGN) has disclosed Current Deferred Revenue for 3 consecutive years, with $412000.0 as the latest value for Q4 2018.

  • Quarterly Current Deferred Revenue fell 20.16% to $412000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $412000.0 through Dec 2018, down 20.16% year-over-year, with the annual reading at $412000.0 for FY2018, 20.16% down from the prior year.
  • Current Deferred Revenue hit $412000.0 in Q4 2018 for Evogene, down from $516000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $967000.0 in Q4 2016 to a low of $412000.0 in Q4 2018.
  • Historically, Current Deferred Revenue has averaged $631666.7 across 3 years, with a median of $516000.0 in 2017.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 46.64% in 2017 and later fell 20.16% in 2018.
  • Year by year, Current Deferred Revenue stood at $967000.0 in 2016, then tumbled by 46.64% to $516000.0 in 2017, then fell by 20.16% to $412000.0 in 2018.
  • Business Quant data shows Current Deferred Revenue for EVGN at $412000.0 in Q4 2018, $516000.0 in Q4 2017, and $967000.0 in Q4 2016.